Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01TesamorelinPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 8 completed trials, 1,729 people given it.10 reported

   152 people1 study

   • Thinking scores edged up, and this was one modest trial. 152 adults aged 55 to 87 took tesamorelin or a dummy injection daily for about five months. Sixty six of them already had mild memory problems. The drug group did a little better at tests of planning and mental flexibility, by enough to separate from chance....

     Archives of Neurology, 2012 · 152 people

2. 02Tesamorelin / IpamorelinBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,507 people given it.9 reported

   152 people1 study

   • A low dose of tesamorelin nudged thinking in the right direction in older adults. A hundred and fifty two people aged 55 to 87 took it or a dummy shot for five months, and sixty six of them already had mild memory trouble. The gain showed up mainly in planning and mental flexibility. IGF-1 more than doubled while...

     Archives of Neurology, 2012 · 152 people

3. 03SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported

   139 people3 studies1 found nothing

   • Children with a growth hormone deficiency grew faster on sermorelin, in a study with nobody to compare them against. 110 children injected it nightly for up to a year. Their growth roughly doubled, from about four centimetres a year to eight at six months, settling near seven by a year. About three quarters responded...

     Journal of Clinical Endocrinology and Metabolism, 1996 · 110 people

   • found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...

     Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people

   • A short course of injections put older men's growth hormone back to young-adult levels. 10 healthy older men injected this fragment of growth hormone releasing hormone twice a day for 14 days. Their growth hormone across a full day, and their IGF-1, rose to levels that could not be told apart from young men's. Ten men...

     Journal of Clinical Endocrinology & Metabolism, 1992 · 10 people

4. 04OctreotidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 140 people given it.3 reported

   115 people1 study

   • In acromegaly the drug brought the hormone down in about half the patients. A hundred and fifteen people with the condition, which is caused by too much growth hormone, were treated across several hospitals. Growth hormone fell below the target level in 53 of every 100, and IGF-1 came back to normal in 68 of every...

     Annals of Internal Medicine, 1992 · 115 people

5. 05HexarelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 105 people given it.7 reported

   112 people5 studies

   • The older you are, the less growth hormone hexarelin gets out of you. 60 people across four age groups each got a single dose into a vein. Young adults released nearly twice as much growth hormone as elderly people, 1,829.7 against 951.1 in the units used. The stress hormone response went the other way, trending...

     European Journal of Endocrinology, 1997 · 60 people

   • Body fat blunts the response, so the heavier you are the less hexarelin does. 21 healthy elderly people each got a single shot under the skin. The more fat someone carried, the lower their growth hormone peak, and fat mass predicted the response better than anything else measured. Being male or female made no...

     Clinical Endocrinology, 1998 · 21 people

   • As a pituitary test hexarelin works for growth hormone and fails for cortisol. 19 patients were tested both with hexarelin and with the old method of driving blood sugar down with insulin. Hexarelin pushed growth hormone far higher, 67.1 against 26.9 mU/L, and the two tests agreed on whether growth hormone was normal...

     Clinical Endocrinology, 1999 · 19 people

6. 06MecaserminPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 76 people given it.6 reported

   200,535 people5 studies

   • Men with naturally higher IGF-1 in their blood get prostate cancer somewhat more often. Nearly 200,000 men were followed for about seven years. 5,402 were diagnosed with prostate cancer and 295 died of it. The higher a man's level, the higher his risk, and a genetic analysis pointed the same way, which makes a real...

     International Journal of Cancer, 2021 · 199,698 people

   • Low blood sugar is the main hazard of this treatment, and this registry shows how often it actually happens. 306 patients were tracked from 2008 to 2021, most of them with severe IGF-1 deficiency. 80 had at least one low blood sugar episode and 224 had none. Serious episodes were rare. Children who had low blood sugar...

     Journal of Clinical Endocrinology and Metabolism, 2023 · 306 people

   • The treatment helps children who do not have Laron syndrome as well, just less. 242 children across ten European countries were entered in an ongoing registry. Among the 138 never treated before, first year height gain was bigger in the 21 with Laron syndrome than in the 117 without. Even so, more than half the non...

     European Journal of Endocrinology, 2021 · 242 people

7. 07MK-677Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 65 people given it.11 reported

   65 people2 studies1 found nothing

   • found nothingIt shifted muscle and fat, and it did not make anyone stronger or more able. 65 adults aged 60 to 81 took MK-677 or a dummy pill daily for up to two years. Growth hormone and IGF-1 climbed back to young-adult levels. Lean tissue rose about 1.1 kg while the dummy group lost about half a kilo. Strength and everyday...

     Annals of Internal Medicine, 2008 · 65 people

   • The trial was stopped early over a heart safety signal, and most of what it measured did not improve. 123 older people recovering from a broken hip took MK-677 or a dummy pill. Walking speed improved and IGF-1 rose. Most other measures of function did not move. The study was halted before it finished because of...

     Archives of Gerontology and Geriatrics, 2011 · number of people not given

8. 08MK-677 with ipamorelinBlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 182 people given it.7 reported

   65 people1 study

   • MK-677 worked in the longest study any of these drugs has had, and the gains were modest. 65 healthy adults aged 60 to 81 took a 25 mg pill or a dummy pill every day for two years. Nobody knew which they had. Growth hormone and IGF-1 climbed back into the range of a healthy young adult, with no serious harms. Lean...

     Annals of Internal Medicine, 2008 · 65 people

9. 09SomatropinBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 84 people given it.9 reported

   60 people1 study

   • Take growth hormone away from adults who need it and most things get worse. 60 adults with a pituitary shortage, treated for about ten years, were switched onto a dummy for four months. Their IGF-1 fell sharply. Two aspects of quality of life declined. Waists grew, deep belly fat rose, and cholesterol and an...

     Journal of Clinical Endocrinology and Metabolism, 2012 · 60 people

10. 10Sermorelin / GHRPBlendLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 56 people given it.9 reported

    63 people4 studies1 found nothing

    • found nothingOld pituitaries answered the combined signal as well as young ones did. Twenty six healthy people aged 19 to 96 were given both peptides together into a vein, once. Growth hormone rose sharply in every one of them, and the size of the rise did not fall off with age. That is worth knowing, because age is usually blamed...

      Journal of Clinical Endocrinology and Metabolism, 1998 · 26 people

    • Adding a releasing hormone to a ghrelin type drug roughly doubled the growth hormone response. Twenty patients were tested on two separate days, once with one drug and once with both. In people with a healthy pituitary the peak went from 25.7 to 54.7 units, and in people short of the hormone from 1.3 to 4.0. Flushing...

      European Journal of Endocrinology, 2002 · 20 people

    • Sermorelin lifted old men's growth hormone back to a young man's level, at a dose far above what people inject now. Ten healthy older men took it twice a day for two weeks. By the end, their growth hormone and IGF-1 across a full day matched those of young men. Ten men for two weeks tells you the hormone moved. It...

      Journal of Clinical Endocrinology and Metabolism, 1992 · 10 people

11. 11Ursolic acidSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 16 people given it.6 reported

    16 people1 study1 found nothing

    • found nothingThe entire human record for ursolic acid is sixteen men. 16 healthy men averaging 29 did eight weeks of weight training, seven on training alone and nine also taking ursolic acid capsules three times a day. Body fat percentage fell in the supplemented group. Body weight, body mass index, muscle mass, blood sugar and...

      Korean Journal of Physiology and Pharmacology, 2014 · 16 people

12. 12GHRP-2PeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 102 people given it.7 reported

    15 people1 study1 found nothing

    • found nothingChildren given GHRP-2 up the nose grew faster, and the study had nothing to compare them against. Fifteen short children took it twice and later three times a day for months. Their growth rate rose from under four centimetres a year to about six. The blood marker usually treated as the sign of a growth hormone effect...

      Journal of Endocrinology, 1997 · 15 people

13. 13GalaninPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 21 people given it.

    13 people3 studies3 found nothing

    • found nothingGalanin shuts down insulin in dogs and rodents, and in people it did nothing of the kind. Seven healthy men were given a sugar load on its own, and again with galanin at two high infusion rates. Blood sugar and insulin came out the same either way, though growth hormone still rose. The authors' own conclusion is the...

      Diabetes, 1989 · 7 people

    • found nothingHuman galanin drove growth hormone up eightfold and left the pancreas completely alone. Six healthy volunteers were infused for an hour while their blood sugar was deliberately held high. Insulin, glucagon and blood sugar behaved exactly as they had without it. The body cleared half the galanin in under four minutes,...

      Diabetologia, 1993 · 6 people

    • found nothingThe first time galanin was given to people, it set off a surge of growth hormone. Ten healthy volunteers were infused for an hour at one of two rates. Growth hormone climbed many times over, further at the higher rate. The hormone behind milk production rose a little. Stress and thyroid hormones did not move, and...

      The Lancet, 1986 · number of people not given

14. 14GHRP-6PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 42 people given it.8 reported

    9 people1 study1 found nothing

    • found nothingThe longest anyone has been kept on this peptide, and the response was already fading by the end. Nine healthy young men had GHRP-6 or salt water dripped in for thirty-four hours. Total growth hormone output roughly doubled and IGF-1 rose modestly. The natural pulse pattern did not change. By the end the pituitary was...

      Journal of Clinical Endocrinology and Metabolism, 1993 · 9 people

15. 15CJC-1295PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.9 reported

    number of people not given2 studies1 found nothing

    • One shot lifted growth hormone for over a week, and that is the whole of what was measured. Healthy adults got a single injection of CJC-1295 or a dummy injection, and nobody involved knew which. Growth hormone in the blood then ran two to ten times higher for six days or more. IGF-1, the hormone the liver makes in...

      Journal of Clinical Endocrinology & Metabolism, 2006 · number of people not given

    • found nothingThe drug lifted growth hormone without flattening the body's own rhythm. Healthy men got a single dose. A week later their lowest growth hormone readings were about seven and a half times higher than before, average growth hormone was up by roughly half, and IGF-1 was up by roughly half. The pulses the body normally...

      Journal of Clinical Endocrinology & Metabolism, 2006 · number of people not given

16. 16AOD-9604PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.5 reported

    number of people not given1 study1 found nothing

    • found nothingAOD9604 was tested properly for weight loss and it did not work. Six separate trials compared it with a dummy, and none of them delivered the fat loss the drug was built for. It did not change the growth hormone marker in the blood, and it did not change how people handled sugar. Its side effect profile looked the...

      Journal of Endocrinology and Metabolism, 2013 · number of people not given

17. 17Modified GRF 1-29PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.9 reported

    number of people not given1 study

    • The peptide did move hormone levels, and this trial tested a different version from the one usually sold. Healthy adults aged 21 to 61 got either rising doses or a dummy, with nobody knowing which. A single injection pushed growth hormone several fold higher for six days or more, and IGF-1 stayed up for a week and a...

      Journal of Clinical Endocrinology and Metabolism, 2006 · number of people not given

18. 18CJC-1295 / IpamorelinBlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 20 people given it.9 reported

    number of people not given1 study

    • One injection kept growth hormone raised for the better part of a week. Healthy adults were given a single shot of CJC-1295 or a dummy shot, and their blood was tracked afterwards. Growth hormone ran several times higher for six days or more, and IGF-1, the hormone it drives, stayed up for nine to eleven days. The...

      Journal of Clinical Endocrinology and Metabolism, 2006 · number of people not given

19. 19CJC-1295 with GHRP-2BlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.8 reported

    number of people not given1 study

    • Putting the two drug types together does push growth hormone higher than either one alone. Healthy older adults got GHRH, GHRP-2, or both, through a drip over 24 hours. The pair beat each drug on its own. The extra boost from pairing them was three times bigger in young people than in older ones. It was bigger in...

      Journal of Clinical Endocrinology and Metabolism, 2004 · number of people not given

20. 20CJC-1295 with GHRP-6BlendLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 9 people given it.7 reported

    number of people not given1 study

    • A single shot of the long-acting version lifts growth hormone for days in healthy adults. That much is solid. Growth hormone ran two to ten times above its usual level for six days or more. The growth factor IGF-1 stayed high for nine to eleven days. Half a dose is still in the body a week later. Read the label with...

      Journal of Clinical Endocrinology and Metabolism, 2006 · number of people not given

21. 21CJC-1295 with ipamorelin and GHRP-2BlendModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 117 people given it.5 reported

    number of people not given2 studies

    • A single shot of the long-acting version keeps growth hormone up for days. Here that is the problem, not the selling point. In healthy adults growth hormone ran two to ten times above its usual level for six days or more. IGF-1 stayed high for nine to eleven days. After repeat doses, IGF-1 was still above where it...

      Journal of Clinical Endocrinology and Metabolism, 2006 · number of people not given

    • One hunger-hormone type peptide plus GHRH is enough to show the effect. That is the point to take from this study. Healthy older adults given the pair through a 24 hour drip made more growth hormone than with either drug alone. Nobody has tested adding a second peptide that presses the same switch as the first....

      Journal of Clinical Endocrinology and Metabolism, 2004 · number of people not given

22. 22DermorphinPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 11 people given it.2 reported

    11 people1 study

    • Again a probe of how the pituitary gland works, not a treatment. Eleven people with a hormone producing tumour in the pituitary were given dermorphin. Prolactin did not budge in any of them, unlike in healthy people. Growth hormone rose in everyone except the three with the largest tumours. The point was to learn...

      Metabolism, 1985 · 11 people

23. 23Sermorelin with ipamorelinBlendModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 117 people given it.8 reported

    number of people not given2 studies

    • Sermorelin was put head to head with growth hormone itself, in children who were short of it. That is the sort of evidence behind sermorelin's approval as a medicine. Be clear about who was studied. These were children with a diagnosed hormone shortage, treated so they would grow. They were not healthy adults hoping...

      Acta Paediatrica Supplement, 1993 · number of people not given

    • The two-switch idea behind this vial has worked in people, but with different drugs. Healthy older adults given a hunger-hormone type peptide together with GHRH made more growth hormone than with either one alone. That is the best proof that pairing the two kinds does something real. It is not proof for this product....

      Journal of Clinical Endocrinology and Metabolism, 2004 · number of people not given

24. 24OxandroloneHormonePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.5 reported

    number of people not given1 study

    • Oxandrolone left badly burned children with stronger bones five years later. 119 children with burns over 30 percent of their body got the drug twice a day for up to two years, or a dummy pill. Treated children had stronger bones across the whole body and lower spine, and grew taller faster early on. Fewer had bones...

      Shock, 2016 · number of people not given